Related Experiment Video
Updated: Jun 16, 2025
10:31
Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
12.4K
Immunotherapy Platform That Conjugates Antigen to Complement C3-Targeted Liposomes Induces a Robust Adaptive Immune
R G Barber1, Steven Cherry1, Sydney Stephens1
1WWAMI School of Medical Education, University of Alaska Anchorage, 3211 Providence Drive, Anchorage, AK 99508, USA.
International Journal of Molecular Sciences
|June 13, 2025
Summary
This study introduces a novel liposome platform for cancer immunotherapy that targets antigen-presenting cells (APCs). The liposomes effectively deliver antigens, stimulating robust cellular and humoral immune responses in mice.
Area of Science:
- Immunology
- Biotechnology
- Cancer Research
Background:
- Activating immunosuppressed antigen-presenting cells (APCs) in the tumor microenvironment is crucial for effective cancer immunotherapy.
- Current strategies aim to enhance APC activation for improved therapeutic outcomes.
Purpose of the Study:
- To evaluate a novel liposome-based immunotherapy platform for targeted delivery of antigens and adjuvants to APCs.
- To assess the platform's ability to elicit robust adaptive immune responses in vivo.
Main Methods:
- Conjugation of a model antigen (OVA-C) to C3-liposomes, incorporating a toll-like receptor 4 agonist (MPLA).
- Vaccination of C57BL/6 mice with the developed liposomes.
- Analysis of humoral and cellular adaptive immune responses using ELISA and ELISpot assays.
Main Results:
- Liposomes with exterior-bound antigen (OVA-C) demonstrated improved antigen loading and complement C3-targeted delivery to APCs.
- Vaccinated mice showed significantly enhanced humoral and cellular adaptive immune responses compared to controls.
- Female mice exhibited a stronger IgG antibody response than males when vaccinated with MPLA + OVA-C liposomes.
Conclusions:
- The C3-liposome platform facilitates efficient antigen delivery and APC targeting, initiating potent adaptive immunity.
- This liposomal delivery system shows promise for developing advanced cancer immunotherapies.
- Sex-based differences in immune response were observed, highlighting potential factors for future research.
Keywords:
antigen presenting cellscancercomplement C3 targetingimmune modulationliposomal deliverytoll-like receptor agonistMore Related Videos
07:18HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL
Published on: April 11, 2011
15.4K
11:07Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination
Published on: April 29, 2015
13.2K
Related Concept Videos
01:27Tumor Immunotherapy
493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
01:26Antigens Involved in Adaptive Immunity
477
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
Complete Antigens
Complete antigens possess both immunogenicity and...
477
01:20Special Features of Adaptive Immunity
783
The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
783
01:24B Cell Activation and Differentiation
1.7K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.7K
01:27Cytotoxic T Cells-mediated Immune Response
861
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
861
01:31Hybridoma Technology
14.2K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.2K